Entrada Therapeutics (TRDA) Projected to Post Quarterly Earnings on Tuesday

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.78) per share and revenue of $10.98 million for the quarter.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $12.25 million for the quarter, compared to analysts' expectations of $11.95 million. On average, analysts expect Entrada Therapeutics to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Entrada Therapeutics Price Performance

Shares of TRDA stock traded up $0.18 during trading hours on Friday, reaching $9.23. The stock had a trading volume of 88,458 shares, compared to its average volume of 126,707. Entrada Therapeutics has a twelve month low of $7.10 and a twelve month high of $21.79. The firm has a market capitalization of $350.31 million, a PE ratio of 5.81 and a beta of 0.04. The firm has a 50-day simple moving average of $9.48 and a 200-day simple moving average of $14.04.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Monday, March 31st.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.